Kindred Biosciences (KIN) Misses Q4 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/25/2026
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Oil drops more than $2 despite new US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Wattmore and Eos Energy strike non-exclusive storage software deal
- Grand Canyon Education places CFO on leave amid stock trade probe
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Funds sell $44bn in semiconductors on AI concerns
- RUM Group signs $13.7 billion GPU services deal, issues warrants
Kindred Biosciences (KIN) PT Lowered to $18 at B.Riley/FBR
March 7, 2019 3:20 AM ESTB.Riley/FBR analyst Andrew D\'Silva lowered the price target on Kindred Biosciences (NASDAQ: KIN) to $18.00 (from $19.25) while maintaining a Buy rating.
... More